Company Encyclopedia
View More
name
T&K
301263.SZ
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the form of tablets, pills, injections, and essential oils; medical technology and technology transfer services; and medical devices. It also operates as an agent for pharmaceutical products; and offers medical and sanitary materials, masks, sutures, surgical staplers, vascular clips and clip appliers, etc., as well as non-prescription drugs.
3.095 T
301263.SZMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking100/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.33%C
    • Profit Margin3.45%C
    • Gross Margin58.46%B
  • Growth ScoreD
    • Revenue YoY-10.31%D
    • Net Profit YoY-82.71%E
    • Total Assets YoY5.30%B
    • Net Assets YoY-0.85%D
  • Cash ScoreC
    • Cash Flow Margin2896.08%A
    • OCF YoY-10.31%D
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio24.84%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    T&K: Wholly-owned subsidiary Huabo Kaisheng intends to win the bid for the national centralized procurement of drugs

    T&K's wholly-owned subsidiary Huabo Kaisheng Biotechnology Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement and is expected to be selected. The proposed selection prices for Huabo Kaisheng's Fumaric Acid Lurasidone Tablets and Alendronate Sodium Tablets are 30.49 yuan/box and 6.2 yuan/box, respectively, suitable for the treatment of allergic rhinitis, urticaria, and osteoporosis

    Zhitong·
    SZ
    301263
    -1.50%
    Zhitong·
    SZ
    301263
    -1.50%

    T&K: Net profit loss of 5.6796 million yuan in the third quarter, a decrease of 118.57%

    T&K announced that the revenue for the third quarter was 179 million yuan, an increase of 1.02%; the net profit loss was 5.6796 million yuan, a decrease of 118.57%. The revenue for the first three quarters was 526 million yuan, a decrease of 8.13%; the net profit was 31.4052 million yuan, a decrease of 73.00%

    Zhitong·
    SZ
    301263
    -1.50%
    Zhitong·
    SZ
    301263
    -1.50%

    T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trials

    According to the Zhitong Finance APP, T&K announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct a seamless adaptive clinical trial for CKBA cream for the indication of rosacea in Phase II/III

    Zhitong·
    SZ
    301263
    -1.50%
    Zhitong·
    SZ
    301263
    -1.50%

    T&K: The drug registration application for Methanesulfonic Acid Safinamide Tablets has been accepted

    T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets issued by the National Medical Products Administration. This drug is a selective inhibitor of monoamine oxidase B (MAO-B) and is primarily used for the treatment of adult patients with idiopathic Parkinson's disease as an adjunct therapy to levodopa

    Zhitong·
    SZ
    301263
    -1.50%
    Zhitong·
    SZ
    301263
    -1.50%

    T&K: The application for the domestic production drug registration and marketing license of Dydrogesterone Tablets has been accepted

    According to the Zhitong Finance APP, T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" for the domestic production drug registration application for Dienogest Tablets issued by the National Medical Products Administration. Dienogest, as a selective progestin, is used to treat endometriosis, alleviating pain symptoms and stabilizing endometrial tissue, with advantages of good tolerance and low adverse reaction rates

    Zhitong·
    SZ
    301263
    -1.50%
    Zhitong·
    SZ
    301263
    -1.50%
    © 2025 Longbridge｜Disclaimer